Aurigene Pharmaceutical Services, a unit of Indian drugmaker Dr. Reddy’s Laboratories, is planning to spend (PDF) $40 million to build a production facility for therapeutic proteins, antibodies and viral vectors.
The facility will be located at Genome Valley, a biotech park in Hyderabad, India. It's expected to be completed and fully operational by the first half of 2024, the company said in a May 22 press release.
The company also said an additional fill-finish line is under construction and is expected to be validated before the end of 2024.
“With this expansion in biotherapeutics CDMO, we will be positioned to provide integrated services from clinical research to commercial manufacturing for small and large molecules,” Akhil Ravi, Aurigene’s chief executive, said in the release.
“Investing in emerging technologies and health solutions reinforces our aim to triple our existing reach to touch over 1.5 billion patients worldwide by 2030," Ravi added.
This isn't the only investment by Dr. Reddy's or a subsidiary lately. In late February, the parent company shelled out about $105 million to acquire Mayne Pharma’s U.S. copycats portfolio.
The deal gave the drugmaker 45 commercially available products, four in the pipeline and 40 approved but unmarketed drugs.